Atossa Genetics

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Atossa Therapeutics Inc (NASDAQ:ATOS)'s selective estrogen receptor modulator (Z)-endoxifen is being evaluated in a Phase 2 study aimed at preventing the progression of ductal carcinoma in situ (DCIS), the presence of abnormal cells inside a milk duct in the breast, to breast cancer.  The Phase 2 platform study, titled “Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS),” has been initiated by Quantum Leap Healthcare Collaborative (QLHC), a charitable organization established in 2005 as a collaboration between medical researchers at the University of California, San Francisco and Silicon Valley entrepreneurs.

Atossa Therapeutics' (Z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situ

40-site U.S. trial enrolling more than 300 patients could significantly change the way DCIS is treated and reduce possibly unnecessary surgery SAN FRANCISCO , Oct. 30, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC) announces the enrollment launch for the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS), a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer. The study is evaluating three investigational endocrine therapy arms: (Z)-endoxifen, a selective estrogen receptor modulator (SERM) in development by Atossa Therapeutics (Nasdaq: ATOS); HAVAH T+Ai™, a proprietary combination of testosterone (T) and anastrozole (Ai) that targets the androgen and estrogen receptor pathways in development by Havah Therapeutics; and ORSERDU® (elacestrant), the only FDA approved oral selective estrogen receptor degrader (oSERD) in development by Stemline Therapeutics Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group.

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Dr. Steven Quay calls for nutritional guidelines for adolescent girls to reduce future breast cancer SEATTLE , Oct. 11, 2023 /PRNewswire/ -- Physician-Scientist Dr. Steven Quay, MD, PhD is calling for nutritional guidelines for adolescent girls to reduce processed and fast-food consumption during puberty to prevent future breast cancer. His recommendation is based on recent research showing a link between consumption of a particular set of chemicals produced by the high temperatures used to fry or grill foods that have a high level of sugars and the induction of pre-cancerous changes during pubertal breast development.

Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later

SEATTLE, WA / ACCESSWIRE / September 18, 2023 / One in eight women will be diagnosed with breast cancer during their lifetime. However, breast cancer does not affect all women in the same way, and individual physiology plays a huge factor.

Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment

SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023.

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

Analysts at Cantor Fitzgerald have initiated coverage on Atossa Therapeutics Inc (NASDAQ:ATOS) with an ‘Overweight' rating and a $5 price target on their belief that positive trial data readouts for Atossa's investigational breast cancer drug will drive upward earnings estimate revisions and send the firm's stock higher. Atossa's shares traded up on Friday morning, adding 11.5% to US$0.83.

Atossa Therapeutics' upcoming breast cancer trial results expected to drive stock higher

Atossa Therapeutics Inc (NASDAQ:ATOS) is targeting three different stages of the breast cancer continuum with its proprietary oral form of Endoxifen, a drug that combines estrogen receptor degradation, suppression, and protein kinase C (PKC) beta inhibition. Atossa CEO Dr.

Atossa Therapeutics is targeting multiple stages of the breast cancer continuum with oral Endoxifen

Analysts at Maxim Group reiterated their 'Buy' rating on Atossa Therapeutics Inc (NASDAQ:ATOS) after the biopharmaceutical company reported its second quarter 2023 financial results on August 14.  They also maintained their price target of US$4 on the company which is developing medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments.

Atossa Therapeutics has analysts bullish as it advances breast cancer therapeutic

Atossa Therapeutics, Inc. (NASDAQ:ATOS ) Q2 2023 Earnings Conference Call August 14, 2023 9:00 AM ET Company Participants Eric Van Zanten - Vice President of Investor and Public Relations Steven Quay - President and Chief Executive Officer Greg Weaver - Executive Vice President and Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Edward Woo - Ascendiant Capital Operator Good morning, ladies and gentlemen, thank you for standing by and welcome to the Atossa Therapeutics Q2 2023 Conference Call. Please be advised today's conference is being recorded.

Atossa Therapeutics, Inc. (ATOS) Q2 2023 Earnings Call Transcript

Atossa Therapeutics Inc (NASDAQ:ATOS) unveiled its second quarter financial results highlighted by a strong balance sheet to support the company in completing its Phase 2 trials for (Z)-endoxifen. The Seattle-based biotech finished the three-month period ending June 30, 2023 with $99.4 million of cash and cash equivalents, according to its results statement.

Atossa Therapeutics rides strong momentum in 2Q to clinical advancements and corporate expansion

SEATTLE, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces financial results for the quarter ended June 30, 2023, and provides an update on recent company developments.

Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

SEATTLE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines to address significant unmet needs in cancer, today announced that it will provide a business update and report financial results for the second quarter 2023 on Monday, August 14, 2023. Company management will host a conference call to review the results at 9:00 a.m. ET / 6:00 a.m. PT on August 14, 2023.

Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023

Atossa Therapeutics Inc (NASDAQ:ATOS) has received what's known as a no objection letter from Health Canada in response to its clinical trial application, the company announced.  This means the company is clear to begin enrolling patients and opening sites in Canada for its Phase 2 EVANGELINE study.of its patented breast cancer treatment.

Atossa Therapeutics gets green light to open enrollment for Phase 2 breast cancer trial in Canada

SEATTLE, July 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that Health Canada has issued a “No Objection Letter” following the Company's Clinical Trial Application for its Phase 2 EVANGELINE study. This means Atossa can open sites and enroll patients in their Phase 2 EVANGELINE study throughout Canada.

Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada

SEATTLE, WA / ACCESSWIRE / July 12, 2023 / One in eight women will be diagnosed with breast cancer during their lifetime. However, breast cancer does not affect all women in the same way, and individual physiology plays a huge factor.

50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis

Analysts at Maxim Group have reiterated a 'buy' rating on Atossa Therapeutics Inc (NASDAQ:ATOS) shares after the biotech recently announced an enrollment update for its ongoing P2 KarismaEndoxifen study, and also revealed a change of CFO. The P2 trial, which is evaluating daily doses of endoxifen in premenopausal women with measurable breast density for six months, has 170 patients enrolled so far.

Maxim upbeat on Atossa Therapeutics after recent updates

Atossa Therapeutics Inc (NASDAQ:ATOS) announced that 170 patients have been enrolled across its ongoing Phase 2 Karisma-Endoxifen study of its oral formulation of (Z)-endoxifen in premenopausal women with measurable breast density.   The company said it expects the trial to be fully enrolled in the fourth quarter of 2023.

Atossa Therapeutics provides update on Phase 2 breast density trial enrollment

SEATTLE, July 10, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that 170 patients have been enrolled in the Company's ongoing Phase 2 Karisma-Endoxifen clinical trial. Atossa expects the study to fully enroll in the fourth quarter of 2023.

Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

Wearable Devices Ltd

When it comes to potentially profitable penny stocks, some can create unimaginable fortunes for patient investors. Others, not so much.

3 Penny Stocks to Make Your ‘Get Rich' Dreams Come True

Atossa Therapeutics Inc (NASDAQ:ATOS), which is developing medicines aimed at oncology and breast cancer, announced a sponsored research agreement with Weill Cornell Medicine to address treatment challenges in triple negative breast cancer (TNBC). The Seattle-based clinical-stage biopharma company said the aim is to determine if treating TNBC with extracellular vesicles carrying the estrogen receptor (ER) will convert the tumor to ER+ and render it sensitive to treatment with Selective Estrogen Receptor Modulators (SERM), including Atossa's own (Z)-endoxifen.

Atossa Therapeutics strikes sponsored research deal with Weill Cornell Medicine for triple negative breast cancer

SEATTLE, July 06, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces a strategic, sponsored research agreement with Weill Cornell Medicine to study the potential of inducing estrogen receptor (ER) expression in triple-negative breast cancer (TNBC). The goal of this research is to determine if treating TNBC with extracellular vesicles carrying the ER will convert the tumor to ER+ and render it sensitive to treatment with Selective Estrogen Receptor Modulators (SERM), including Atossa's proprietary (Z)-endoxifen.

Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer

Atossa Therapeutics Inc (NASDAQ:ATOS), which is developing medicines aimed at oncology and breast cancer, revealed that six patients have been dosed with its proprietary selective estrogen receptor modulator (SERM), (Z)-endoxifen, in the ongoing Phase 2 I-SPY 2 clinical trial. The Seattle-based clinical-stage biopharma company said (Z)-endoxifen is being evaluated as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive (ER+) invasive breast cancer, whose tumors are predicted to be sensitive to endocrine therapy, but for whom chemotherapy is expected to provide little, or no benefit.

Atossa Therapeutics hits 30% enrollment for (Z)-Endoxifen arm of ongoing I-SPY 2 clinical trial

SEATTLE and SAN FRANCISCO , June 28, 2023 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, and Quantum Leap Healthcare Collaborative™ ("Quantum Leap") today announced that six patients have been dosed with Atossa's proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the ongoing Phase 2 I-SPY 2 clinical trial. (Z)-endoxifen is being evaluated as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive (ER+) invasive breast cancer whose tumors are predicted to be sensitive to endocrine therapy but for whom chemotherapy is expected to provide little or no benefit.

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

Atossa Therapeutics Inc (NASDAQ:ATOS) announced that its board of directors has approved a share repurchase program with authorization to purchase up to $10 million of Atossa common stock through December 31, 2023. The clinical-stage biopharmaceutical firm said under the program, shares will be repurchased from time to time in open market transactions, privately negotiated block transactions, or by other means.

Atossa Therapeutics launches $10M share buyback program

SEATTLE, June 27, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that its Board of Directors has approved a share repurchase program with authorization to purchase up to $10 million of its common stock through December 31, 2023.

News for Atossa Genetics Stock (ATOS)